Patent intelligence · AT
AT E213650
INKLUSIONSKOMPLEXE VON RADIOHALOGENIERTEN FETTSÄUREN IN EINER ZYKLODEXTRINE
INKLUSIONSKOMPLEXE VON RADIOHALOGENIERTEN FETTSÄUREN IN EINER ZYKLODEXTRINE
Patent details — AT E213650
- Jurisdiction
- AT
- Status
- expired
- Grant date
- Mar 15, 2002
- Expiration
- Mar 10, 2022
- Applicant
- CIS BIO INT [FR]
- CPC classes
- A61K 47/ 48 A I, A61K 51/ 12 A I, A61K/476951, A61K/511268
Quick answer
AT E213650 (INKLUSIONSKOMPLEXE VON RADIOHALOGENIERTEN FETTSÄUREN IN EINER ZYKLODEXTRINE) is held by CIS BIO INT [FR]. Status: expired. Granted Mar 15, 2002. Expires Mar 10, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CIS BIO INT [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 47/ 48 A I, A61K 51/ 12 A I, A61K/476951, A61K/511268, A61K47/48, A61K51/12
More from CIS BIO INT [FR]
Related pharmaceutical patents in our USPTO index.
-
GB 2467012
Lanthanide (III) ion complexing compounds, luminescent lanthanide (III) ion complexes and use thereof as fluorescent labels
granted -
EP 1913959
Radioaktive Metallkomplexe enthaltend eine Tridentat-Komplex-Sequenz
granted -
US 7238340
Monoamine, diamide, thiol-containing metal chelating agents
granted -
DE 69534943
TECHNETIUM-99M MARKIERTE PEPTIDE ZUR BILDFORMUNG
granted -
DK 0759786
Somatostatinbindende peptidmetal-chelatkonjugater
granted -
US 2005207973
Stabilization of radiopharmaceutical compositions using hydrophilic 6-hydroxy chromans
expired -
US 2005180918
Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
expired -
EP 1381397
STABILISIERUNG VON RADIOPHARMAZEUTISCHEN ZUSAMMENSETZUNGEN MIT EINEM HYDROPHILEN THIOETHER ODER EINEM HYDROPHILEN 6-HYDROXY-CHROMAN
expired
Frequently asked questions
What is US patent E213650?
AT E213650 (INKLUSIONSKOMPLEXE VON RADIOHALOGENIERTEN FETTSÄUREN IN EINER ZYKLODEXTRINE) is held by CIS BIO INT [FR]. Status: expired. Granted Mar 15, 2002. Expires Mar 10, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AT E213650?
CIS BIO INT [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 18 pharmaceutical patents for this assignee.
When does AT E213650 expire?
Our index shows an expiration date of Mar 10, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.